In Brief: P&G/Regeneron
Executive Summary
P&G/Regeneron: Agreement to develop therapeutics for muscle diseases and disorders is worth up to $28.8 mil. to Regeneron. The collaboration will draw on Procter & Gamble's skeletal muscle disease research and Regeneron's discovery of proteins "critical to the formation of a functional nerve-muscle unit," P&G says. P&G will purchase $10 mil. in Regeneron stock in the first half of 1997 and will make up to five $3.75 mil. annual payments to Regeneron. "Profits will be shared equally from any products jointly developed and marketed," P&G says...